FY2025 EPS Forecast for Aclaris Therapeutics Cut by Analyst

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Research analysts at Wedbush dropped their FY2025 earnings estimates for Aclaris Therapeutics in a research report issued on Thursday, November 6th. Wedbush analyst M. Fan now expects that the biotechnology company will post earnings per share of ($0.51) for the year, down from their previous estimate of ($0.50). The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.82) per share. Wedbush also issued estimates for Aclaris Therapeutics’ Q4 2025 earnings at ($0.14) EPS and FY2029 earnings at ($0.43) EPS.

Several other equities research analysts have also recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aclaris Therapeutics in a research note on Wednesday, November 5th. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of Aclaris Therapeutics in a report on Monday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $8.71.

Aclaris Therapeutics Price Performance

NASDAQ ACRS opened at $2.30 on Monday. The company’s fifty day moving average is $2.06 and its two-hundred day moving average is $1.71. The firm has a market capitalization of $249.16 million, a price-to-earnings ratio of -1.68 and a beta of 0.43. Aclaris Therapeutics has a 52-week low of $1.05 and a 52-week high of $5.17.

Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Thursday, November 6th. The biotechnology company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.01. Aclaris Therapeutics had a negative net margin of 802.03% and a negative return on equity of 34.01%. The firm had revenue of $3.30 million during the quarter, compared to analysts’ expectations of $1.59 million.

Institutional Investors Weigh In On Aclaris Therapeutics

Several large investors have recently modified their holdings of ACRS. Alps Advisors Inc. lifted its position in shares of Aclaris Therapeutics by 36.4% during the 1st quarter. Alps Advisors Inc. now owns 78,782 shares of the biotechnology company’s stock worth $121,000 after buying an additional 21,022 shares during the period. Decheng Capital LLC lifted its holdings in shares of Aclaris Therapeutics by 78.3% during the first quarter. Decheng Capital LLC now owns 4,041,736 shares of the biotechnology company’s stock valued at $6,184,000 after acquiring an additional 1,775,069 shares during the period. Invesco Ltd. lifted its holdings in shares of Aclaris Therapeutics by 409.0% during the first quarter. Invesco Ltd. now owns 57,079 shares of the biotechnology company’s stock valued at $87,000 after acquiring an additional 45,864 shares during the period. HighTower Advisors LLC boosted its stake in shares of Aclaris Therapeutics by 20.2% in the 1st quarter. HighTower Advisors LLC now owns 316,064 shares of the biotechnology company’s stock valued at $484,000 after purchasing an additional 53,116 shares in the last quarter. Finally, Algert Global LLC bought a new stake in shares of Aclaris Therapeutics in the 1st quarter worth about $61,000. 98.34% of the stock is currently owned by institutional investors.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.